Skip to content

Preliminary study on recombinant human soluble thrombomodulin (rTM) administration for treatment of pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection

Preliminary study on recombinant human soluble thrombomodulin (rTM) administration for treatment of pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection - Recombinant human soluble thrombomodulin (rTM) for treatment of pneumonia-induced ARDS complicated with DIC and sepsis, including avian influenza virus infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020358
Enrollment
3
Registered
2015-12-28
Start date
2015-12-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection

Interventions

Drip infusion of 380 U/kg of rTM q24 hours for maximum 6 days.

Sponsors

National Hospital for Pediatrics, Nanoi, Vietnam
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Severe ARDS complicated with DIC and sepsis. Patients who fulfill all of the followings (1-5) within 72 hours from PICU admission 1) The patients who admitted the PICU-NHP 2) Age: 1 month -15 years old 3) DIC score is within ISTH DIC criteria (Score 5 or more). 4) PaO2/FiO2 ratio (P/F ratio) less than 100 mmHg in arterial blood gas analysis. 5) No severe left ventricular dysfunction 6) Chest X ray abnormal shadow (consolidation, ground-glass opacity, or nodular shadow) 7) Patients provide written informed consent prior to initiation of any study procedures. Patients who or whose attorney are able to understand and comply with planned study procedures. 2.Avian influenza virus infection induced ARDS complicated with DIC and sepsis. Patients who fulfill all of the followings (1-9) within 72 hours from PICU admission 1) Contact with sick or dead poultry 2) Positive result of rapid diagnostic test for influenza A, or avian influenza viral genomes are positive with PCR. 3) Patients with 2 or more of the following symptoms. Fever, Cough, Dyspnea, Sore throat, Nasal congestion or rhinorrhea, Headache, Myalgia or arthralgia 4) The patients who admitted the PICU-NHP 5) Age: 1 month -15 years old 6) DIC score is within ISTH DIC criteria (Score more more than 5) 7) PaO2/FiO2 ratio (P/F ratio) less than 300 mmHg in arterial blood gas analysis 8) Chest X ray abnormal shadow (consolidation, ground-glass opacity, or nodular shadow) 9) Patients provide written informed consent prior to initiation of any study procedures. Patients who or whose attorney are able to understand and comply with planned study procedures.

Exclusion criteria

Exclusion criteria: Patients who fulfill any of the followings are excluded 1. Patients with severe renal dysfunction (creatinine clearance < 10mL/min) 2. Patients with bleeding symptoms. 3. Patients whom the treating doctor deems, for any reason, to be ineligible.

Design outcomes

Primary

MeasureTime frame
The change of plasma thrombomodullin concentration

Secondary

MeasureTime frame
1. Observation of clinical course 1.1. Status of DIC (1) DIC score(ISTH) (2) Bleeding symptoms (3) Vital signs and physical examination findings (4) Other laboratory findings; e.g. proinflammatory cytokines 1.2. Status of ARDS (1) P/F ratio (2) Duration of fever (3) Duration of mechanical ventilation including CPAP (4) Vital signs, physical examination findings and SpO2 (5) Chest X ray findings Extent of infiltration: 0=No infiltration, 1=Unilateral, 2=bilateral (6) Other laboratory findings; e.g. blood gas analysis 1.3. The change of liver function and renal function 2. Outcome 3. The etiology of pneumonia-induced ARDS complicated with DIC and sepsis

Countries

Asia(except Japan)

Contacts

Public ContactJin Takasaki

National Center for Global Health and Medicine Department of respiratory medicine

jintakajj@gmail.com+81-3-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026